Intimal hyperplasia: the nemesis of cardiovascular intervention.
Waltham
Matthew
M
Harris
John
J
D000818:Animals; D002340:Carotid Artery Diseases / Q000473:pathology / Q000517:prevention & control; D017536:Carotid Artery, Common / Q000187:drug effects* / Q000473:pathology / Q000601:surgery; D017985:Dalteparin / Q000008:administration & dosage / Q000627:therapeutic use; D017984:Enoxaparin / Q000008:administration & dosage / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D006965:Hyperplasia / Q000188:drug therapy / Q000517:prevention & control; D019919:Prosthesis Implantation / Q000009:adverse effects; D012756:Sheep; D017539:Tunica Intima / Q000187:drug effects* / Q000473:pathology
D017984:Enoxaparin; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D017985:Dalteparin